Medpace Holdings, Inc. (MEDP) |
| 530.19 -8.04 (-1.49%) 07-13 16:00 |
| Open: | 527.275 |
| High: | 544.418 |
| Low: | 523.995 |
| Volume: | 261,761 |
| Market Cap: | 15,142(M) |
| PE Ratio: | 33.32 |
| Exchange: | NASDAQ Global Select |
| Industry: | Medical - Diagnostics & Research |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 663.32 |
| Resistance 1: | 567.91 |
| Pivot price: | 526.73 |
| Support 1: | 490.68 |
| Support 2: | 442.95 |
| 52w High: | 628.916 |
| 52w Low: | 306.704 |
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
| EPS | 15.880 |
| Book Value | 20.950 |
| PEG Ratio | 3.27 |
| Gross Profit | 67.577 |
| Profit Margin (%) | 17.19 |
| Operating Margin (%) | 20.03 |
| Return on Assets (ttm) | 17.5 |
| Return on Equity (ttm) | 77.3 |
Mon, 13 Jul 2026
Medpace Holdings, Inc. (MEDP) Stock Analysis: Is the Current Valuation Justified Amidst Strong Revenue Growth? - DirectorsTalk Interviews
Sat, 11 Jul 2026
Medpace Holdings (MEDP) Rallies As A More Cautious Narrative Questions The Valuation - Yahoo Finance
Fri, 10 Jul 2026
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Medpace Holdings, Inc. (MEDP) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Tue, 07 Jul 2026
A Look at Medpace Holdings Inc (MEDP) After 3.4% Decline -- GF V - GuruFocus
Mon, 06 Jul 2026
Medpace: The Recovery Narrative Looks Premature (NASDAQ:MEDP) - Seeking Alpha
Sat, 04 Jul 2026
Enterprise value to revenue forward of Medpace Holdings, Inc. – NASDAQ:MEDP - TradingView
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |